Show simple item record

dc.contributor.authorNanou, A
dc.contributor.authorCoumans, FAW
dc.contributor.authorvan Dalum, G
dc.contributor.authorZeune, LL
dc.contributor.authorDolling, D
dc.contributor.authorOnstenk, W
dc.contributor.authorCrespo, M
dc.contributor.authorFontes, MS
dc.contributor.authorRescigno, P
dc.contributor.authorFowler, G
dc.contributor.authorFlohr, P
dc.contributor.authorBrune, C
dc.contributor.authorSleijfer, S
dc.contributor.authorde Bono, JS
dc.contributor.authorTerstappen, LWMM
dc.date.accessioned2020-11-11T12:14:36Z
dc.date.issued2018-04-10
dc.identifier.citationOncotarget, 2018, 9 (27), pp. 19283 - 19293
dc.identifier.issn1949-2553
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4222
dc.identifier.eissn1949-2553
dc.identifier.doi10.18632/oncotarget.25019
dc.description.abstractPURPOSE: The presence of Circulating Tumor Cells (CTCs) in Castration-Resistant Prostate Cancer (CRPC) patients is associated with poor prognosis. In this study, we evaluated the association of clinical outcome in 129 CRPC patients with CTCs, tumor-derived Extracellular Vesicles (tdEVs) and plasma levels of total (CK18) and caspase-cleaved cytokeratin 18 (ccCK18). EXPERIMENTAL DESIGN: CTCs and tdEVs were isolated with the CellSearch system and automatically enumerated. Cut-off values dichotomizing patients into favorable and unfavorable groups of overall survival were set on a retrospective data set of 84 patients and validated on a prospective data set of 45 patients. Plasma levels of CK18 and ccCK18 were assessed by ELISAs. RESULTS: CTCs, tdEVs and both cytokeratin plasma levels were significantly increased in CRPC patients compared to healthy donors (HDs). All biomarkers except for ccCK18 were prognostic showing a decreased median overall survival for the unfavorable groups of 9.2 vs 21.1, 8.1 vs 23.0 and 10.0 vs 21.5 months respectively. In multivariable Cox regression analysis, tdEVs remained significant. CONCLUSIONS: Automated CTC and tdEV enumeration allows fast and reliable scoring eliminating inter- and intra- operator variability. tdEVs provide similar prognostic information to CTC counts.
dc.formatElectronic-eCollection
dc.format.extent19283 - 19293
dc.languageeng
dc.language.isoeng
dc.publisherImpact Journals, LLC
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleCirculating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients.
dc.typeJournal Article
dcterms.dateAccepted2018-03-17
rioxxterms.versionofrecord10.18632/oncotarget.25019
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2018-04-10
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfOncotarget
pubs.issue27
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.publication-statusPublished
pubs.volume9
pubs.embargo.termsNot known
icr.researchteamCancer Biomarkers
icr.researchteamProstate Cancer Targeted Therapy Group
dc.contributor.icrauthorCrespo, Mateus
dc.contributor.icrauthorRescigno, Pasquale
dc.contributor.icrauthorDe Bono, Johann


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0